Experimental Daily Pill Doubles Survival for Pancreatic Cancer Patients

An experimental daily pill, daraxonrasib, has been hailed as a breakthrough, demonstrating the ability to double survival times and improve the quality of life for patients with pancreatic cancer, a notoriously deadly form of the disease. Clinical trials continue to show significant promise in treating this previously almost untreatable cancer.